Microcap Ledger Outlook Therapeutics, Inc. $OTLK
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Iselin, NJ
- Fiscal year end
- September 30
- Shares outstanding
- 243,447,554 [10-Q 2026-08-18]
What the company doesAI summary of filing
Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations of bevacizumab. Its lead product, ONS-5010/LYTENAVA, is approved in the European Union and United Kingdom for treating wet age-related macular degeneration (wet AMD) and launched in Germany and the UK in June 2025; a regulatory application for US FDA approval is under review with a decision expected by December 31, 2025. The company makes money by selling or licensing its approved product and aims to commercialize ONS-5010/LYTENAVA directly in the United States if approved, while exploring partnerships for other markets. Outlook is at a commercial stage in Europe and the UK, and is pre-revenue in the United States pending FDA approval. [10-K 2025-12-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | — | −$47.83M | −$43.78M | $11.24M | [10-Q 2026-08-18] |
| FY ended Sep 2025 | $1.41M | −$62.42M | −$51.83M | $8.08M | [10-K 2025-12-19] |
| FY ended Sep 2024 | — | −$75.37M | −$68.79M | $14.93M | [10-K 2025-12-19] |
- Quarterly cash burn
- −$14.59M
- Cash runway Estimate
- ~2.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-01-21 | 31,980,072 | [10-K/A 2025-01-23] |
| 2025-02-12 | 32,017,179 | [10-Q 2025-02-14] |
| 2025-05-12 | 33,568,023 | [10-Q 2025-05-15] |
| 2025-08-11 | 44,419,529 | [10-Q 2025-08-14] |
| 2025-12-16 | 64,114,399 | [10-K 2025-12-19] |
| 2026-02-13 | 83,067,190 | [10-Q 2026-02-17] |
| 2026-05-12 | 120,863,252 | [10-Q 2026-05-15] |
| 2026-08-14 | 243,447,554 | [10-Q 2026-08-18] |
- Shelf registration
- S-3 filed 2026-07-17; declared effective 2026-07-21 [S-3 2026-07-17]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-30] |
| 2026-06-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-26] |
| 2026-02-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-18] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-14 | Jahr Robert Charles | buy | 151,515 | — | [4 2026-08-14] |
| 2026-08-14 | Kenyon Lawrence A | buy | 101,010 | — | [4 2026-08-14] |
| 2026-08-12 | Sukhtian Ghiath M. | buy | 2,525,252 | $0.99 | [4 2026-08-14] |
| 2026-07-29 | Sukhtian Faisal Ghiath | buy | 95,398 | $1.05 | [4 2026-07-29] |
| 2026-06-02 | Haddadin Yezan Munther | buy | 29,000 | $0.83 | [4 2026-06-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Listing notice or transfer |
| 2026-09-18 | 8-K | Other events |
| 2026-08-27 | 8-K | Director or officer change |
| 2026-08-19 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-18 | 10-Q | Quarterly report |
| 2026-08-17 | NT 10-Q | Notice of late quarterly report |
| 2026-08-14 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 8-K | Other events |
| 2026-08-14 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-12 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-12 | 8-K | Results of operations; Other events |
Alerts for $OTLK
Email me when Outlook Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.